Quantification of Early-Stage Myeloid-Derived Suppressor Cells in Cancer Requires Excluding Basophils
- 31 March 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 8 (6), 819-828
- https://doi.org/10.1158/2326-6066.CIR-19-0556
Abstract
Myeloid derived suppressor cells (MDSC) are a heterogeneous group of immature cells that accumulate in the peripheral blood and tumor microenvironment and are barriers to cancer therapy. MDSCs serve as prognostic biomarkers and are targets for therapy. On the basis of surface markers, three subsets of MDSCs have been defined in humans: granulocytic, monocytic, and early stage (e-MDSC). The markers attributed to e-MDSCs overlap with those of basophils, which are rare circulating myeloid cells with unrecognized roles in cancer. Thus, we asked whether e-MDSCs in circulation and the tumor microenvironment include basophils. On average, 58% of cells with e-MDSC surface markers in blood and 36% in ascites from patients with ovarian cancer were basophils based on CD123(high) expression and cytology, whereas cells with immature features were rare. Circulating and ascites basophils did not suppress proliferation of stimulated T cells, a key feature of MDSCs. Increased accumulation of basophils and basogranulin, a marker of basophil degranulation, were observed in ascites compared to serum in patients with newly diagnosed ovarian cancer. Basophils recruited to the tumor microenvironment may exacerbate fluid accumulation by their release of proinflammatory granular constituents that promote vascular leakage. No significant correlation was observed between peripheral basophil counts and survival in patients with ovarian cancer. Our results suggest that studies in which e-MDSCs were defined solely by surface markers should be reevaluated to exclude basophils. Both immaturity and suppression are criteria to define e-MDSCs in future studies.Other Versions
Funding Information
- Roswell Park Comprehensive Cancer Center
- NCI (P30CA016056)
- Roswell Park-UPCI Ovarian Cancer SPORE (P50CA159981, R01CA172105, R01CA188900, T32085183, T32CA108456)
This publication has 41 references indexed in Scilit:
- Identification and quantification of basophils in the airways of asthmatics following segmental allergen challengeCytometry Part A, 2014
- Phosphatidylserine-Targeting Antibody Induces M1 Macrophage Polarization and Promotes Myeloid-Derived Suppressor Cell DifferentiationCancer Immunology Research, 2013
- Protective and pathological roles of mast cells and basophilsNature Reviews Immunology, 2013
- Myeloid-Derived Suppressor Cells Suppress Antitumor Immune Responses through IDO Expression and Correlate with Lymph Node Metastasis in Patients with Breast CancerThe Journal of Immunology, 2013
- Inflammatory Monocytes Recruited to Allergic Skin Acquire an Anti-inflammatory M2 Phenotype via Basophil-Derived Interleukin-4Immunity, 2013
- Coordinated regulation of myeloid cells by tumoursNature Reviews Immunology, 2012
- Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 proteinThe Journal of Experimental Medicine, 2008
- Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell–suppressive activityBlood, 2008
- Prospective isolation of human clonogenic common myeloid progenitorsProceedings of the National Academy of Sciences of the United States of America, 2002
- Mass, charge, and subcellular localization of a unique secretory product identified by the basophil-specific antibody BB1Journal of Allergy and Clinical Immunology, 2001